Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
Improving the lives of people suffering from mental illness and substance use disorders
Developing improved pharmaceuticals based on innovative drug delivery technologies
Providing evidence-based digital therapies to improve treatment outcomes
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
We Care
Shedding light on lives affected by addiction and the road to recovery
Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.
Key News
JUNE 14, 2021
Orexo´s partner Gesynta Pharma reports progresses with the OX-MPI study
JUNE 2, 2021
ZUBSOLV's patent portfolio is strengthened with two new patents
APRIL 29, 2021
Q1 2021 Interim Report
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
Orexo Social
@OrexoABpubl
24 June 2021
According to new data presented by @CDCgov, which applies to the period Dec. 1, 2019 – Nov. 30, 2020, the number of… https://t.co/m12zkqUifW
@OrexoABpubl
21 June 2021
According to new data from @CDCgov overdose deaths continues to surge. In parallel multiple businesses confront a w… https://t.co/yuiYyEnKDS
@OrexoABpubl
18 June 2021
WOMEN IN WELLNESS series: Thanks to @ChayaWeiner @AuthorityMag for a great interview with our colleague Mikaela Odl… https://t.co/8AcHswmY1K
News Flow
Press Releases & News
Orexo’s Partner Gesynta Pharma announces progresses in phase II study of OX-MPI and submits IND with FDA
Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents
Invitation to presentation of Orexo´s Q1 Interim Report, on April 29 at 2 pm CET
Orexo continues to strengthen IP rights for ZUBSOLV®
Financial Snapshot
Group net revenues
621 MSEK
LTM1
Group EBITDA
-44 MSEK
LTM1
US Pharma segment EBIT
322 MSEK
LTM1
Cash position
726 MSEK
Q1 2021
1 Last Twelve Months, Q220-Q121, for more information about financial development Link